These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34023149)

  • 41. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
    Huang R; Liu J; Wang J; Wu C
    Aliment Pharmacol Ther; 2021 May; 53(9):1040-1041. PubMed ID: 33831236
    [No Abstract]   [Full Text] [Related]  

  • 42. Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.
    Tang K; Cheng H; Wang H; Guo Y
    Medicine (Baltimore); 2023 Feb; 102(6):e32894. PubMed ID: 36820558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?
    Chien RN
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1699-701. PubMed ID: 22097937
    [No Abstract]   [Full Text] [Related]  

  • 45. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
    Chiu SY; Chang KC; Hu TH; Chien RN
    Aliment Pharmacol Ther; 2021 May; 53(9):1042-1043. PubMed ID: 33831240
    [No Abstract]   [Full Text] [Related]  

  • 47. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
    Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
    J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of chronic hepatitis B in severe liver disease.
    Fung J; Lai CL; Yuen MF
    World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
    Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
    BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward.
    Yuan BH; Zhu YK; Li RH
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e342. PubMed ID: 33716140
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.
    Kim DS; Jeon MY; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Clin Mol Hepatol; 2019 Sep; 25(3):283-293. PubMed ID: 30419649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Choi J; Kim GA; Han S; Lim YS
    Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
    Hall S; Howell J; Visvanathan K; Thompson A
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
    J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-a "knock-out" is yet to be delivered.
    Tonthat AV; Zhou K
    Aliment Pharmacol Ther; 2022 May; 55(10):1342-1343. PubMed ID: 35472182
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t) ide-naïve patients with chronic hepatitis B.
    Kwon YJ; Lee HS; Park MJ; Shim SG
    Niger J Clin Pract; 2015; 18(6):796-801. PubMed ID: 26289520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues.
    Lampertico P; Papatheodoridis GV
    Gastroenterology; 2020 Jan; 158(1):42-44. PubMed ID: 31706943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.